Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q
Source: 0001731122-25-000258
Chunk: 3

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
,313 
  
    Total Other Income (Expense) 
     (2,706,078) 
     (259,046) 
     6,420,440  
     (549,960)

    NET LOSS 
    $(7,252,394) 
    $(4,529,121) 
    $(51,464,429) 
    $(13,704,149)

    BASIC AND DILUTED LOSS PER SHARE 
    $(0.04) 
    $(0.07) 
    $(0.32) 
    $(0.21)

     WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC AND DILUTED 
     161,825,205  
     65,852,497  
     160,909,289  
     65,166,625 

See accompanying notes to the unaudited condensed consolidated
financial statements.

3

RENOVARO INC. AND SUBSIDIARIES

 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE
LOSS

(UNAUDITED)

    For the Three Months Ended 
    For the Six Months Ended

    December 31, 
    December 31,

    2024 
    2023 
    2024 
    2023

    Net Loss 
    $(7,252,394) 
    $(4,529,121) 
    $(51,464,429) 
    $(13,704,149)
  
    Other Comprehensive Income (Loss) 

    Foreign Currency Translation, net of taxes 
     (10,144,818) 
     37,252  
     (3,676,757) 
     2,651 

    Comprehensive Loss 
    $(17,397,212) 
    $(4,491,869) 
    $(55,141,186) 
    $(13,701,498)

See accompanying notes to the unaudited condensed consolidated
financial statements.

4

RENOVARO INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’
EQUITY

(UNAUDITED)

    # of Series A Preferred Shares 
    Series A Preferred Shares Amount 
    # of Common Shares 
    Common Shares Amount 
    Additional Paid-In Capital 
    Accumulated Deficit 
    Accumulated Other Comprehensive Income 
    Total